Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

NCT06672536

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Sinocelltech Ltd.
Enrollment	82 participants

Key Eligibility Criteria

Inclusion (3)

- Signed informed consent form.
- Agee45 years, d80 years male or femal.
- The study eye must meet the following criteria: Diagnosis of nAMD;Active MNV lesions secondary to nAMD; Total area of all types of lesions d12 optic disc areas; BCVA of the study eye 73\~19 letters.

Exclusion (13)

- Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye.
- Significant APD or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination.
- Aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye.
- The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine.
- MNV caused by non-nAMD exists in the study eye .

... and 8 more (see full listing online)

Locations (1 total)

Tianjin Medical University Eye Hospital, Tianjing, China